Fig. 1



A
Testis
Placenta
Brain
Lung
Breast
Colon
Liver
Stomach
Kidney
Prostate
Pancreas
Ovary
Spleen
Skin
Myocard
Endometrium
PBMCs
Breast cancer
Breast cancer
Cancer cell lines
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
B
Relative expression
100000
10000
1000
100
10
1
Normal tissues
Breast cancer
C
Relative expression
100000
10000
1000
100
10
1
Colon
Lung
Ovary
Melanoma
Prostate
Breast
Cervix

Fig. 1




D
Relative expression (%)
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
siRNA#2
MCF-7
BT-549
E
untreated
ns-siRNA
siRNA#1
siRNA#2
GT468
MCF-7
Aktin
GT468
BT-549
Aktin
F
Breast
Lung
Colon
Liver
Brain
Testis
Placenta
Breast-Ca
GT468
Aktin
G

Fig. 2






Fig. 3



A
Chemokinesis (%)
140
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
MCF-7
BT-549
B
Chemotaxis (%)
140
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
MCF-7
BT-549
C
Invasion (%)
140
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
MCF-7
BT-549

Fig. 4



A
Proliferation (%)
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
siRNA#2
MCF-7
BT-549
B
Cells (%)
100
80
60
40
20
0
MCF-7
BT-549
G0/G1
S
G2/M
G0/G1
S
G2/M
untreated
ns-siRNA
siRNA#1
siRNA#2
C
MCF-7
BT-549
1
10
100
1000
FL4-H:: Annexin
1
10
100
1000
FL4-H:: Annexin
Camptothecin
untreated
ns-siRNA
siRNA#1
siRNA#2

Fig. 5



untreated
control Ab
anti-GT468
BT-549
MCF-7
Proliferation (%)
120
100
80
60
40
20
0
0
1
2
4
µg/ml

Fig. 6



A
Cyclin D1
Relative expression (%)
120
100
80
60
40
20
0
untreated
ns-siRNA
siRNA#1
siRNA#2
MCF-7
BT-549
B
untreated
ns-siRNA
siRNA#1
siRNA#2
Cyclin D1
MCF-7
Aktin
Cyclin D1
BT-549
Aktin
C
untreated
ns-siRNA
siRNA#1
pAKT
AKT
MCF-7
Actin
pAKT
AKT
BT-549
Actin
D
untreated
control Ab
anti-GT468
pAKT
AKT
MCF-7
Actin
pAKT
AKT
BT-549
Actin

Fig. 7



Peptide ELISA
specific peptide
control peptide
absorbtion
1,80
1,60
1,40
1,20
1,00
0,80
0,60
0,40
0,20
0,00
4E9 1H9
9B6 2A9
59D6 2F2
61C11 2B5
78H11 1H6
supernatant

Fig. 8



merge
hybridoma supernatant
GT468-eGFP
4E9 1H9
9B6 2A9
59D6 2F2

Fig. 9



Proliferation Inhibition
4E9 1H9
9B6 2A9
59D6 2F2
proliferation (%)
120
100
80
60
40
20
0
BT-549
Caov-3
EFO-21
MCF-7
MDA-MB-231
cell lines

Fig. 10



A
CrELISA
GT468 lysate
mock lysate
E405
1,8
1,6
1,4
1,2
1,0
0,8
0,6
0,4
0,2
0,0
22-1A-1
22-2A-1
22-9B-1
23-33A-1
23-19A-1
supernatant
B
Peptide ELISA
specific peptide
control peptide
E405
1,4
1,2
1
0,8
0,6
0,4
0,2
0
F11#33 F7 D12
4A12 2D4 1A10
4E9 1D12 2D4
supernatant

Fig. 11



22-1A-1
22-2A-1
22-9B-1
23-33A-1
23-19A-1
4A12 2D4 1A10
4E9 1D12 2D4
counts
GT468
HEK mock
HEK GT468

Fig. 12

- HEK mock
+ HEK GT468
GT468
22-1A-1
22-2A-1
22-9B-1
23-33A-1
23-19A-1
4A12 2D4 1A10
4E9 1D12 2D4

Fig. 13

Peptide	Sequence
1	MKVFKFIGLMILLTS
2	KFIGLMILLTSAFSA
3	LMILLTSAFSAGSGQ
4	LTSAFSAGSGQSPMT
5	FSAGSGQSPMTVLCS
6	SGQSPMTVLCSIDWF
7	PMTVLCSIDWFMVTV
8	LCSIDWFMVTVHPFM
9	DWFMVTVHPFMLNND
10	VTVHPFMLNNDVCVH
11	PFMLNNDVCVHFHEL
12	NNDVCVHFHELHLGL
13	CVHFHELHLGLGCPP
14	HELHLGLGCPPNHVQ
15	LGLGCPPNHVQPHAY
16	CPPNHVQPHAYQFTY
17	HVQPHAYQFTYRVTE
18	HAYQFTYRVTECGIR
19	FTYRVTECGIRAKAV
20	VTECGIRAKAVSQDM
21	GIRAKAVSQDMVIYS
22	KAVSQDMVIYSTEIH
23	QDMVIYSTEIHYSSK
24	IYSTEIHYSSKGTPS
25	EIHYSSKGTPSKFVI

Peptide	Sequence
26	SSKGTPSKFVIPVSC
27	TPSKFVIPVSCAAPQ
28	FVIPVSCAAPQKSPW
29	VSCAAPQKSPWLTKP
30	APQKSPWLTKPCSMR
31	SPWLTKPCSMRVASK
32	TKPCSMRVASKSRAT
33	SMRVASKSRATAQKD
34	ASKSRATAQKDEKCY
35	RATAQKDEKCYEVFS
36	QKDEKCYEVFSLSQS
37	KCYEVFSLSQSSQRP
38	VFSLSQSSQRPNCDC
39	SQSSQRPNCDCPPCV
40	QRPNCDCPPCVFSEE
41	CDCPPCVFSEEEHTQ
42	PCVFSEEEHTQVPCH
43	SEEEHTQVPCHQAGA
44	HTQVPCHQAGAQEAQ
45	PCHQAGAQEAQPLQP
46	AGAQEAQPLQPSHFL
47	EAQPLQPSHFLDISE
48	LQPSHFLDISEDWSL
49	HFLDISEDWSLHTDD
50	ISEDWSLHTDDMIGS
51	SEDWSLHTDDMIGSM

Hybridoma	Reactivity (Peptide)
22-1A-1	50+51
22-2A-1	18, 26-31, 42
22-9B-1	27, 29-31
23-33A-1	47+48
23-19A-1	48+49

Hybridoma	Reactivity (Sequence)
F11#33 F7 D12	VFSLSQSSQRPNC
4A12 2D4 1A10	APQKSPWLTKPC
4A9 1D12 2D4	APQKSPWLTKPC

Fig. 14



SK-BR-3 (72h)
MCF-7 (120h)
15µg/ml
45µg/ml
Proliferation (%)
0
20
40
60
80
100
120
control
4A12 2D4 1A10
4E9 1D12 2D4

Fig. 15



GT468
mock
42H11 1C11 2B2
51G6 2H3 2B4
78H11 1H6
16-5B-1
20-11A-1
29-1A-2
29-8B-1
38-10B-1
38-1A-1
44-3A-2
GT468
FSC
GT468
mock
45-2A-1
45-8A-2
48-3B-1
48-4A-1
49-3A-1
49-8A-1
51-1A-1
53-13A-2
54-4B-2
56-4A-2
GT468
FSC

Fig. 16A



NUG-C4
MCF-7
MDA-MB-468
SK-BR-3
42H11 1C11 2B2
78H11 1H6
20-11A-1
22-1A-1
29-1A-2
GT468
PI

Fig. 16B



NUG-C4
MCF-7
MDA-MB-468
SK-BR-3
35-50A-2a
48-3B-1
51-1A-1
53-13A-2
54-4B-2
GT468
PI

Fig. 17



GT468
42H11 1C11 2B2
51G6 2H3 2B4
16-5B-1
20-11A-1
22-1A-1
29-1A-2
29-8B-1
38-1A-1
44-3A-2
45-8A-2
49-8A-1
51-1A-1
+
-
- HEK mock
+ HEK GT468

Fig. 18



MDA-MB-468
MelHo
SK-BR-3
MCF-7
Proliferation (%)
control
56-4A-2
53-29A-1
53-13A-2
51-1A-1
49-3A-1
48-4A-1
48-3B-1
45-8A-2
45-2A-1
38-10B-1
38-1A-1
35-50A-2a
35-48B-1
10 µg/ml
50 µg/ml

Fig. 19




Fig. 20A



Relative expression
100000
10000
1000
100
10
1
Adrenal gland
Brain
Breast
Colon
Duodenum
Endometrium
Esophagus
Fallopian tube
Gall bladder
Ileum
Kidney
Liver
Lung
Lymph node
Ovary
Pancreas
PBMCS act.
PBMCs rest.
Placenta
Prostate
Rectum
Skeletal muscle
Skin
Spleen
Stomach
Testis
Thymus
Thyroid
Urinary bladder
Relative expression
100000
10000
1000
100
10
1
Lung cancer

Fig. 20B



Relative expression
100000
10000
1000
100
10
1
Ovarian cancer
Gastric cancer
Prostate cancer
Pancreatic cancer
Relative expression
100000
10000
1000
100
10
1
Renal cell cancer
Liver cancer
Sarcoma
Thyroid cancer
Head and neck cancer

Fig. 21



HEK293-GT468
SK-Br-3
MelHO
NUGC4
SK-BR-3
BEWO
JAR
HCT-15
LnCaP
HeLa
MDA-MB-468
Marker
JEG-3
JIMT-1
MelHO
SK-BR-3
LA1-55n
PC-3
BT-20
NCI-H929

Fig. 22



MDA-MB-468
NUGC4
10μg/ml
50μg/ml
Proliferation (%)
120
100
80
60
40
20
0
62-9B-1
78H11 1H6
44-3A-2
62-9B-1
78H11 1H6
44-3A-2

Fig. 23




Fig. 24



1000
800
600
400
200
0
Tumor volume (mm³)
PBS
78H11 1H6
0
3
6
9
14
17
20
Days
PBS
44-3A-2
0
3
6
9
14
17
20
Days


Fig. 25

Peptide	Sequence
1	MKVFKFIGLMILLTS
2	KFIGLMILLTSAFSA
3	LMILLTSAFSAGSGQ
4	LTSAFSAGSGQSPMT
5	FSAGSGQSPMTVLCS
6	SGQSPMTVLCSIDWF
7	PMTVLCSIDWFMVTV
8	LCSIDWFMVTVHPFM
9	DWFMVTVHPFMLNND
10	VTVHPFMLNNDVCVH
11	PFMLNNDVCVHFHEL
12	NNDVCVHFHELHLGL
13	CVHFHELHLGLGCPP
14	HELHLGLGCPPNHVQ
15	LGLGCPPNHVQPHAY
16	CPPNHVQPHAYQFTY
17	HVQPHAYQFTYRVTE
18	HAYQFTYRVTECGIR
19	FTYRVTECGIRAKAV
20	VTECGIRAKAVSQDM
21	GIRAKAVSQDMVIYS
22	KAVSQDMVIYSTEIH
23	QDMVIYSTEIHYSSK
24	IYSTEIHYSSKGTPS
25	EIHYSSKGTPSKFVI
26	SSKGTPSKFVIPVSC
27	TPSKFVIPVSCAAPQ
28	FVIPVSCAAPQKSPW
29	VSCAAPQKSPWLTKP
30	APQKSPWLTKPCSMR
31	SPWLTKPCSMRVASK
32	TKPCSMRVASKSRAT
33	SMRVASKSRATAQKD
34	ASKSRATAQKDEKCY
35	RATAQKDEKCYEVFS
36	QKDEKCYEVFSLSQS
37	KCYEVFSLSQSSQRP
38	VFSLSQSSQRPNCDC
39	SQSSQRPNCDCPPCV
40	QRPNCDCPPCVFSEE
41	CDCPPCVFSEEEHTQ
42	PCVFSEEEHTQVPCH
43	SEEEHTQVPCHQAGA
44	HTQVPCHQAGAQEAQ
45	PCHQAGAQEAQPLQP
46	AGAQEAQPLQPSHFL
47	EAQPLQPSHFLDISE
48	LQPSHFLDISEDWSL
49	HFLDISEDWSLHTDD
50	ISEDWSLHTDDMIGS
51	SEDWSLHTDDMIGSM

Hybridoma	Reactivity (Peptide)
29-1A-2	27, 29, 30
29-8B-1	49-51
35-48B-1	13
44-3A-2	31, 32
49-3A-1	29-31
49-8A-1	37, 38
51-1A-1	36-37
53-13A-2	33, 34
54-4B-2	34, 37
62-9B-1	36, 37

Hybridoma	Reactivity (Sequence)
78H11 1H6	WSLHTDDMIGSM

Fig. 26


DNA copy number
15000
10000
5000
0
P=0.011
P=0.021
P=0.030
PBS
51-1A-1
62-9B-1
44-3A-2